ARTICLE | Clinical News
Topsalysin: Phase III data
November 16, 2015 8:00 AM UTC
The double-blind, international Phase III PLUS-1 in 479 patients with moderate to severe BPH showed that a single intraprostatic injection of 0.6 ug/g PRX302 met the primary endpoint of improving IPSS...